Skip to main content

Table 5 Health and economic outcomes (ICERs) of the base case analyses

From: Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece

  Liraglutide 1.2 mg Sitagliptin Difference
Discounted life expectancy (years) 14.22 (0.18) 14.09 (0.17) 0.13 (0.23)
Discounted quality-adjusted life expectancy (QALYs) 9.24 (0.12) 9.05 (0.11) 0.19 (0.16)
Discounted total lifetime direct medical costs (€) 39524 (1100) 36727 (1113) 2797 (1468)
 Drug acquisition 15069 11240 3829
 Patient management* 1939 1928 11
 Cardiovascular disease 5858 6170 −312
 Renal disease 1146 1253 −107
 Diabetic foot and neuropathy 6665 7132 −467
 Eye disease 5325 5676 −351
 Hypoglycaemia 3522 3329 193
ICER (€ per QALY gained)    15101
  Liraglutide 1.8 mg Exenatide BID Difference
Discounted life expectancy (years) 14.10 (0.17) 13.96 (0.16) 0.14 (0.23)
Discounted quality-adjusted life expectancy (QALYs) 9.22 (0.12) 9.03 (0.11) 0.19 (0.16)
Discounted total lifetime direct medical costs (€) 43236 (1049) 41934 (1065) 1302 (1492)
 Drug acquisition 18505 14927 3578
 Patient management* 1931 1920 11
 Cardiovascular disease 5544 5980 −436
 Renal disease 1611 1692 −81
 Diabetic foot and neuropathy 5859 6317 −458
 Eye disease 4461 4948 −487
 Hypoglycaemia 5326 6149 −823
ICER (€ per QALY gained)    6818
  1. Values shown are means with SDs in parentheses. *Concomitant medication and screening. QALY = quality-adjusted life year; € = 2013 Euros; ICER = incremental cost-effectiveness ratio.